🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

13 recruiting trials

for Hypereosinophilic Syndrome

The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome NCT07275190NA1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: Blood draw for the laboratory assessment Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils NCT04538937n/a1 site📍 Innsbruck Medical University Innsbruck · Tests: no intervention Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238n/a1 site📍 Toronto University Health Network, Toronto · Tests: Observational European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank NCT02852928n/a3 sites📍 Hanover📍 Ankara📍 Edinburgh Matthias Griese A Study of Depemokimab in Participants of 6 to 11 Years of Age NCT07671001Phase 33 sites📍 Mobile📍 Colorado Springs📍 Watertown GlaxoSmithKline · Tests: Depemokimab A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy NCT07214753n/a28 sites📍 Salerno📍 Padova📍 Teramo AstraZeneca · Tests: benralizumab A Non-interventional, Prospective Study With Benralizumab NCT06422078n/a41 sites📍 Ahrensburg📍 Ansbach📍 Aschaffenburg AstraZeneca Predictive Signature of Benralizumab Response NCT04565483Phase 420 sites📍 Aix-en-Provence📍 Angers📍 Bordeaux Nantes University Hospital · Tests: Benralizumab Prefilled Syringe Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment NCT07444567Phase 346 sites📍 Aurora📍 Bethesda📍 Ann Arbor AstraZeneca · Tests: Benralizumab A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression NCT00091871n/a1 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma NCT07323654Phase 281 sites📍 Lancaster📍 Long Beach📍 Northridge Kymera Therapeutics, Inc. · Tests: KT-621, Placebo Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents NCT06477653Phase 21 site📍 Bethesda National Institute of Allergy and Infectious Diseases (NIAI… · Tests: dupilumab Natural History of Hypereosinophilia and Hypereosinophilic Syndromes NCT04018118n/a1 site📍 Lille University Hospital, Lille · Tests: Biological sample
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy